Stress Myocardial Perfusion Imaging for Assessing Prognosis: An Update  by Bourque, Jamieson M. & Beller, George A.
a
C
J A C C : C A R D I O V A S C U L A R I M A G I N G V O L . 4 , N O . 1 2 , 2 0 1 1
© 2 0 1 1 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 8 X / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c m g . 2 0 1 1 . 1 0 . 0 0 3S T A T E - O F - T H E - A R T P A P E R
Stress Myocardial Perfusion Imaging for
Assessing Prognosis: An Update
Jamieson M. Bourque, MD, MHS, George A. Beller, MD
Charlottesville, VirginiaJACC: CARDIOVASCULAR
IMAGING CME
CME Editor: Ragaven Baliga, MD
This article has been selected as this issue’s CME
activity, available online at www.imaging.onlinejacc.
org by selecting the CME tab on the top navigation
bar.
Accreditation and Designation Statement
The American College of Cardiology Foundation
(ACCF) is accredited by the Accreditation Council
for Continuing Medical Education (ACCME) to
provide continuing medical education for physicians.
The ACCF designates this Journal-based CME
ctivity for a maximum of 1 AMA PRA Category 1
redit(s)™. Physicians should only claim credit com-
mensurate with the extent of their participation in
the activity.
Method of Participation and Receipt of CME
Certificate
To obtain credit for this CME activity, you must:
1. Be an ACC member or JACC: Cardiovascular
Imaging subscriber.
2. Carefully read the CME-designated article avail-
able online and in this issue of the journal.
3. Answer the post-test questions. At least two out
of the three questions provided must be answered
correctly to obtain CME credit.Manuscript received August 24, 2011; revised manuscript received Oc5. Claim your CME credit and receive your certif-
icate electronically by following the instructions
given at the conclusion of the activity.
CME Objective for This Article: At the end of this
activity, the reader of this article should be able to:
describe the pros and cons of stress myocardial
perfusion imaging for assessing prognosis; describe
the clinical context for the appropriate utilization of
myocardial perfusion imaging in determining prog-
nosis; describe the application of stress myocardial
perfusion imaging in special populations such as
diabetic patients, patients with chronic kidney dis-
ease, and patients who have undergone an anatomic-
based noninvasive test such as coronary computed
tomographic angiography that is nondiagnostic or
equivocal; and describe the role of stress myocardial
perfusion imaging in risk prediction.
CME Editor Disclosure: JACC: Cardiovascular
Imaging CME Editor Ragaven Baliga, MD, has
reported that he has no relationships to disclose.
Author Disclosure: The authors have reported that
they have no relationships relevant to the contents of
this paper to disclose.
Medium of Participation: Print (article only); on-
line (article and quiz).
CME Term of Approval:
Issue Date: December, 20114. Complete a brief evaluation. Expiration Date: November 31, 2012
From the Cardiovascular Division, Cardiovascular Imaging Center, Department of Medicine, University of Virginia
Health System, Charlottesville, Virginia. The authors have reported that they have no relationships relevant to the
contents of this paper to disclose.tober 21, 2011, accepted October 27, 2011.
P
m
t
s
B
i
c
p
s
d
c
r
t
o
s
i
m
p
m
n
s
(
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 4 , N O . 1 2 , 2 0 1 1
D E C E M B E R 2 0 1 1 : 1 3 0 5 – 1 9
Bourque and Beller
Stress Myocardial Perfusion Imaging for Assessing Prognosis
1306Stress Myocardial Perfusion Imaging for Assessing Prognosis: An
Update
A strength of nuclear myocardial perfusion imaging (MPI) is the wealth of prognostic data accumulated over 30 years of
experience with this technique. Nuclear MPI can predict outcomes and guide revascularization decisions in symptomatic
patients and is well validated in special populations such as patients with diabetes and chronic renal disease. Known
limitations, such as underestimation of ischemia and radiation burden, are being progressively reduced through advances
such as positron emission tomography absolute flow quantification and fusion with computed tomography, new camera
hardware and software, and stress-only protocols. Advanced statistical techniques and increasing focus on comparative
effectiveness and appropriateness will continue to optimize nuclear cardiology going forward. (J Am Coll Cardiol Img 2011;
4:1305–19) © 2011 by the American College of Cardiology Foundationl
m
t
a
o
e
t
a
p
p
i
a
o
s
v
s
i
w
s
1
w
V
s
e
t
c
fi
wrognosis is primarily related to the degree of
left ventricular dysfunction and the extent
and magnitude of inducible myocardial isch-
emia. Radionuclide variables significantly supple-
ent clinical and electrocardiogram (ECG) stress
est variables in separating high- and low-risk
ubsets with respect to future hard cardiac events.
oth hard (cardiac death or nonfatal myocardial
nfarction [MI]) and soft (e.g., revascularization or
ardiac hospitalization) endpoints are often re-
orted in combination. Readers of the literature
hould be aware that the annual event rates will vary
epending on whether only hard endpoints, or the
ombination of hard and soft endpoints, are used. A
ecent occurrence in studies reporting the prognos-
ic value of radionuclide imaging variables is the use
f all-cause mortality as an endpoint. Caution
hould be exercised when using all-cause mortality
n low- and intermediate-risk populations because
ost deaths in these population are noncardiac (1).
Over the past 30 years, many studies have been
ublished supporting the prognostic value of stress
yocardial perfusion imaging (MPI) in predomi-
antly symptomatic patients (2). Initial clinical
tudies were undertaken with planar thallium-201
201Tl) imaging. They showed that the number of
reversible defects and the presence of abnormal lung
Tl-201 uptake were the most important variables in
identifying high-risk patients with multivessel dis-
ease who had an increased risk of cardiac death or
nonfatal MI. Those patients with normal findings
on perfusion scans had a combined subsequent
death or nonfatal infarction rate of 1% per year.
Transient ischemic left ventricular (LV) cavity
dilation was another high-risk variable that was
associated with an adverse outcome. Transient Tischemic dilation (TID) in most patients is due to
extensive subendocardial ischemia post-stress
that resolves on the resting scan. Later, single-
photon emission computed tomography (SPECT)
imaging supplanted the planar imaging technique
for stress MPI, and the technetium-99m (99mTc)–
abeled perfusion agents sestamibi and tetrofos-
in, replaced Tl-201 as tracers for imaging. The
ransformation to SPECT with these imaging
gents permitted gating of images and calculation
f left ventricular ejection fraction (LVEF) and
nd-systolic and end-diastolic volumes and quan-
itation of regional wall motion or thickening
bnormality extent. These functional variables
rovided additional prognostic information to
erfusion variables (3).
Semiquantitation of perfusion abnormalities us-
ng indices such as the summed stress score (SSS)
nd summed difference score emerged as a more
bjective combined expression of the extent and
everity of hypoperfusion or reversibility. These
ariables were derived from the accepted 17-
egment model for SPECT. The percentage of LV
schemia and total ischemic total perfusion deficit
ere other perfusion variables demonstrated to
eparate patient subgroups. Those with 10% to
2% LV ischemia seemed to have a better outcome
ith revascularization than medical therapy (4).
asodilator and dobutamine pharmacological stres-
ors for MPI in patients unable to adequately
xercise provided prognostic information similar to
hat with exercise stress MPI (5). However, the
ardiac event rates with either normal or abnormal
ndings on pharmacological stress SPECT scans
ere higher than seen with post-exercise stress.
his was attributed to the fact that patients referred
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1307for pharmacological stress were a clinically higher
risk population (e.g., older, more peripheral vascular
disease, more chronic pulmonary disease, previous
stroke).
In recent years, positron emission tomography
(PET) MPI has been well validated as an alterna-
tive to SPECT for the detection of coronary artery
disease (CAD) and determining prognosis. PET
has certain advantages over SPECT, as discussed
later in this review. It clearly can separate high- and
low-risk patients based on extent of inducible per-
fusion abnormalities and/or the percentage of LV
ischemia. Gated PET provides the same functional
information as derived from gated SPECT, al-
though LVEF can be derived at peak stress and rest
rather than just 15 min to 1 h post-stress, as
accomplished with gated SPECT studies. As dis-
cussed, quantification of absolute flow in milliliters/
grams/minute and coronary flow reserve with PET
allows even better risk assessment with MPI than
just evaluating relative tracer uptake for defect
detection.
The purpose of this review is to highlight some
newer aspects of MPI for assessing prognosis,
particularly in light of the COURAGE (Clinical
Outcomes Utilizing Revascularization and Aggres-
sive Drug Evaluation) and BARI-2D (Bypass An-
gioplasty Revascularization Investigation in Type 2
Diabetes) trial results, and the application of stress
MPI in special populations such as patients with
diabetes, patients with chronic kidney disease, and
patients who have undergone an anatomic-based
noninvasive test such as coronary computed tomog-
raphy angiography (CTA) that is nondiagnostic or
equivocal. Stress-only MPI may be considered for
low-risk patients, which reduces radiation burden.
RISK ASSESSMENT USING SPECTMPI
Strength of evidence. With respect to the American
Heart Association/American College of Cardiology
Practice Guidelines on Radionuclide Imaging,
5% of recommendations are identified as having
level of evidence categorized as A (6). This is
because there are few randomized studies compar-
ing outcomes based on nuclear cardiology variables
with other strategies (e.g., exercise ECG testing
alone). Most recently, the WOMEN (What is the
Optimal Method for Ischemia Evaluation in
WomeN?) study randomized women with good
functional capacity and a normal resting ECG to
either exercise ECG testing alone or exercise ECG
testing plus SPECT MPI. There were no differ- 5ences in outcomes (7). This randomized trial should
serve as a model for future SPECT MPI prognostic
studies.
Limitations of the current literature. Some limitations
o the prognostic studies published in the literature
eserve mention. They include populations of pa-
ients that can be quite variable from study to study.
hose studies that include older patients and a large
ercentage of patients with known disease and/or
V dysfunction have a high event rate with both
ormal and abnormal findings on MPI. Imaging
ethodology can differ markedly from study to
tudy. Thus, using quantitative methods
nd attenuation correction may reduce the
ate of false positives. When absolute flow
nd coronary flow reserve are assessed by
uantitative PET, a higher percentage of
ultivessel disease will be detected with a
orresponding lower prevalence of “nor-
al” perfusion attributable to balanced
schemia.
Implications of the COURAGE trial nuclear
substudy. In recent practice patterns, cli-
icians ordering stress MPI studies in
atients with suspected or known CAD
or the purposes of risk stratification
ould refer patients for invasive evaluation
f the study findings were positive for
nducible ischemia. Patients with normal
ndings on scans were most often treated
edically or a workup for a noncardiac
ause of symptoms was initiated. If a
ignificant coronary stenosis was seen on
ngiography that correlated with the myo-
ardial zone of hypoperfusion on SPECT,
percutaneous coronary intervention
PCI) such as stenting was performed.
This practice has been challenged after
ublication of the COURAGE Nuclear
ubstudy, which compared the effective-
ess of PCI  optimal medical therapy
OMT) and OMT alone for ischemic reduction as
ssessed by SPECT MPI (8). Moderate to severe
schemia was defined as 10% LV ischemia. The
rimary endpoint was a 5% reduction in ischemic
yocardium on a 6- to 18-month follow-up scan.
t follow-up, the reduction in ischemic myocar-
ium was greater when PCI was added to OMT
han with OMT alone. More PCI  OMT pa-
ients demonstrated a significant ischemia reduction
33% vs. 19%; p  0.0004), particularly in patients
ith moderate or severe baseline ischemia (78% vs.
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1308included only 314 of the 2,287 COURAGE sub-
jects and was underpowered to detect clinical
events. Moreover, this subgroup was found to have
a lower clinical risk than the overall study cohort.
Accordingly, although substudy subjects with isch-
emia reduction had a lower unadjusted rate of death
or nonfatal MI (p 0.037), especially in those with
oderate to severe baseline ischemia (p  0.001),
hese differences were not significant when Cox risk
djustment was performed (p  0.26 and p  0.08,
espectively) (Fig. 1). However, patients with no
esidual ischemia with treatment had no cardiac
vents. It should be recalled that the main results of
he COURAGE trial showed no difference in
ong-term outcome for stable patients with CAD
andomized to an initial PCI strategy  OMT
ersus OMT alone. The COURAGE Nuclear Sub-
tudy suggests that PCI  OMT reduces ischemia
o a greater degree than OMT alone in patients
ith moderate to severe ischemia, which may be
ssociated with a better long-term prognosis, but
dditional study is required. Thus, the COURAGE
uclear Substudy should be considered as hypoth-
sis generating rather than definitive.
Figure 1. Survival in the COURAGE Study Stratiﬁed by
Presence or Absence of an Ischemia Reduction
Kaplan-Meier survival analysis of the 105 patients in the COURAGE
nuclear substudy with moderate to severe pre-treatment isch-
emia stratiﬁed by the presence or absence of a 5% reduction in
myocardial ischemia after 6 to 18 months of optimal medical
therapy or percutaneous coronary intervention plus optimal
medical therapy. Overall event-free survival was 83.8% versus
66.0% for patients with and without a signiﬁcant ischemia
reduction (p  0.001). In a risk-adjusted Cox model, this differ-
ence was not signiﬁcant (p  0.082). Adapted, with permission,f
from Shaw et al. (8).The findings of this substudy formed the hypoth-
sis for the ISCHEMIA (International Study of
omparative Health Effectiveness with Medical
nd Invasive Approaches) trial. Until the results of
his trial are known, practice has already changed in
hat patients with mild ischemia are now often not
mmediately referred for coronary angiography with
view to performing PCI for a significant stenosis.
MT is the first line of therapy. However, when
schemia is extensive, occurs at a low exercise
orkload, and/or is associated with significant
unctional abnormalities such as a depressed post-
tress ejection fraction, an initial invasive strategy is
ertainly acceptable. The role of follow-up imaging
o evaluate reduction or elimination of the ischemic
urden is still unclear in asymptomatic patients
fter therapy is maximized. Serial imaging certainly
ncreases the costs of medical services and exposes
atients to more radiation. Nevertheless, if medical
herapy is instituted for ischemia reduction and
ymptoms persist or increase, a crossover to an
nvasive strategy is warranted. Finally, it should be
ointed out that in the overall COURAGE trial,
atients with severe CAD (e.g., left main CAD) or
igh-risk ischemia were not randomized.
Stress-only MPI for risk assessment. The conventional
-day SPECT imaging protocol most often entails
erforming a resting SPECT study first, followed
y a stress study using higher doses of the tracer.
his often involves a patient spending 3 to 4 h in
he laboratory for 2 imaging acquisitions and is
ssociated with substantial radiation exposure. Sev-
ral investigators recently reported the prognosis of
atients who had a stress-only study, the findings of
hich were normal after which the resting study
as canceled. This approach is most applicable in
atients with a low- or low-intermediate pre-test
ikelihood of CAD as the cause of presenting
ymptoms. Chang et al. (9) sought to determine
hether normal findings on a stress-only SPECT
PI study conferred the same prognosis as normal
ndings on SPECT derived from stress and rest
mages. They reported all-cause mortality in 16,854
onsecutive patients with normal findings on gated
tress SPECT. Median follow-up was 4.5 years.
pproximately one half of the patients underwent
tress-only SPECT. At follow-up, no significant
ifferences in patient mortality were seen between
he 2 imaging protocols, although the stress-only
ubset received a 61% lower radiopharmaceutical
ose. Figure 2 shows survival of stress-only and
tress and rest SPECT subgroups with male and
emale patients analyzed separately (9). In this
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1309study, patients with diabetes with normal findings
on stress-only SPECT had an outcome comparable
to that of patients with diabetes with normal
findings on stress  rest SPECT.
Duvall et al. (10) examined all-cause and cardiac
mortality in 10,609 patients undergoing stress MPI,
of whom 1,673 had normal findings on stress-only
SPECT. Approximately 80% of these patients un-
dergoing stress-only imaging had low pre-test risk,
and 70% were outpatients. At the end of 40  9
months of follow-up, the cardiac mortality was
0.4% in the group with normal findings on stress-
only SPECT and 0.5% in the rest-stress cohort. No
significant difference between the stress-only and
rest-stress groups was found after controlling for
confounding variables for both all-cause mortality
(p  0.94) and cardiac mortality (p  0.82). It was
estimated that the total radioisotope dose in the
stress-only patients was reduced by 25%.
A stress-only strategy implies that the perfusion
scan findings are normal and that attenuation arti-
facts can be distinguished from true perfusion
defects. Stress-only imaging does not allow us to
compute the TID ratio. However, TID in the
presence of a normal gated SPECT study, observed
in a patient with a low pre-test probability of CAD
who can exercise to an adequate heart rate and/or
workload, is usually artifactual (11). Thus, stress
imaging should probably be done first in clinically
lower risk patients like those who are seen in the
emergency department of hospitals with atypical
Figure 2. Kaplan-Meier All-Cause Mortality Curves for Male and
or Stress-Rest Protocol
There was no difference in outcome in both male (p  0.99) and fe
permission, from Chang et al. (9).symptoms, a normal resting ECG, and no elevationof troponin. If the stress SPECT shows normal
perfusion and function, the resting study can be
cancelled. This approach will increase throughput
in nuclear cardiology laboratories, reduce costs, and
decrease radiation exposure to patients by as much
as 25% to 60% (9,12).
Underestimation of the extent of CAD with SPECT
MPI. It has been well recognized that stress SPECT
PI with either 99mTc sestamibi or 99mTc tetro-
fosmin underestimates the extent of CAD com-
pared with coronary angiographic findings, partic-
ularly with vasodilator imaging (13). In the study by
Lima et al. (14), only 25% of patients with angio-
graphic 3-vessel CAD had perfusion defects or
regional dysfunction in the supply regions of the 3
stenosed coronary arteries (Fig. 3). In fact, 12% had
completely normal findings on SPECT MPI stud-
ies. Berman et al. (15) found that among 101
patients with 50% stenosis of the left main
coronary artery and no previous MI or coronary
revascularization, approximately 40% had a low-risk
scan findings with 10% LV ischemia. This un-
derestimation of CAD may be related to the low
myocardial extraction relative to hyperemic flow
changes of these 99mTc MPI tracers and the fact
that only relative perfusion is evaluated. If all 3
vessels are significantly narrowed or there is a
combination of left main and multivessel CAD,
uniform tracer uptake due to “balanced” ischemia
may lead to rather homogeneous tracer uptake.
Even semiquantitation may not identify this bal-
ale Patients Stratiﬁed by Receipt of a Stress-Only
le (p  0.75) patients in a risk-adjusted Cox model. Adapted, withFem
maanced ischemia and diffuse abnormal flow reserve.
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1310The presence of extensive post-stress regional dys-
function and TID would suggest that the findings
of the perfusion scan are not really normal, espe-
cially if the patient had inducible ischemic ST
depression on the stress ECG or achieved a poor
workload. This underestimation of CAD has
prompted active investigation for quantitating flow
reserve with PET technology (see section on PET
imaging). Currently, research is being conducted in
developing the technology for dynamic SPECT
imaging for evaluating flow reserve (16).
SPECT Abnormalities by CAD Extent
of single-photon emission computed tomography (SPECT) perfu-
rfusion/function abnormalities by obstructive disease pattern on
ronary angiography. Patients with 3-vessel disease have a low
alence of perfusion or functional defects, indicating the underesti-
multivessel disease by SPECT myocardial perfusion imaging.
with permission, from Lima et al. (14). CAD  coronary artery
Annualized Cardiac Events Stratiﬁed by Ischemia Severity and
of Diabetes Mellitus
diac death/nonfatal myocardial infarction rate stratiﬁed by the
ischemia (summed difference score [SDS]) in patients with
) and without (green bars) diabetes mellitus. Event rates
s a function of ischemia (p  0.001). Adapted, with permission,i
et al. (21). Mod-Sev  moderate to severe.SPECIAL POPULATIONS
Risk assessment by MPI in diabetes mellitus. Patients
with diabetes mellitus are a special population on
which there is a robust amount of prognostic
literature. The prevalence of diabetes is increasing
dramatically, with 17 million individuals affected
in the United States and 12% expected to be
diabetic by 2050 (17,18). Patients with CAD and
DM have a 2 to 8 times higher annual death rate,
and cardiac event rates are not decreasing over time
for patients with diabetes as they are in those
without diabetes (17,19–21).
Multiple studies showed that SPECT MPI has
incremental prognostic value over clinical risk fac-
tors and stress ECG for the assessment of cardiac
death and nonfatal MI (21–23). Kang et al. (21)
showed the annual rate of cardiac death and non-
fatal MI to increase from 1% to 2% in patients with
normal findings on SPECT MPI to 7% in those
with moderate to severe ischemia (summed differ-
ence score 4) in 1,271 patients with diabetes (Fig. 4)
(21). Several clinical factors provide additional risk
stratification, including the degree of metabolic
dysfunction present, the ability to exercise, and the
presence of symptoms. Patients requiring combined
insulin and oral agents have a 15- to 21-fold higher
risk of events than those on either type of therapy
alone, and the risk of events is higher in those
taking insulin versus oral agents alone (24,25).
Likewise, the inability to exercise during stress
testing increases the risk of annual cardiac death
6.8-fold (from 1.3% to 8.8%, p  0.001) (26). The
presence of dyspnea significantly increases the risk
of events in those with diabetes, with a 3-fold
higher rate of cardiac death and nonfatal MI than in
asymptomatic patients (13.2% vs. 3.4%, p  0.009)
22). Interestingly, in this study, the event rate with
ngina was not significantly higher than in patients
ithout symptoms (5.6% vs. 3.4%, p  0.44) (22).
The substantial event rate in asymptomatic pa-
ients in this study is not surprising given the high
ates of ischemia in asymptomatic patients in the
andmark DIAD (Detection of Ischemia in Asymp-
omatic Diabetics) study (27). A 5-year follow-up
f the DIAD study found that SPECT MPI
rovides good risk stratification, with a 6-fold
igher risk of cardiac death/nonfatal MI in patients
ith moderate to large defects versus no or small
efects (2.4% vs. 0.4%, p  0.001). However, it
oes not appear that this information leads to
mproved clinical care because there was no signif-Figure 3.
Prevalence
sion or pe
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ischemia versus routine clinical care (27). One
possible explanation for a lack of screening benefit is
the lower risk of this population given that patients
with known CAD were excluded. It is also possible
that increased use of evidence-based medical ther-
apy in both the screened and unscreened groups
minimized the differences between them. This il-
lustration of the power of intensive medical therapy
is consistent with similar effects in the COURAGE
and BARI-2D studies (28,29).
Although there was no benefit with revascular-
ization across the entire BARI-2D population, the
patients requiring coronary artery bypass graft sur-
gery had improved survival, and the substudy look-
ing at events stratified by ischemia is pending (29).
However, data from 2 large observational cohorts
totaling 11,453 patients (2,206 of whom were
diabetic) suggest that patients with significant myo-
cardial ischemia on SPECT MPI have improved
survival with revascularization versus medical ther-
apy in both symptomatic and asymptomatic dia-
betic patients (4,30).
Despite the prognostic benefit of SPECT MPI,
the rate of cardiac events is unacceptably high in
diabetic patients with normal myocardial perfusion
(Fig. 5) (23,31). Giri et al. (23) showed that
diabetic men have a 13.8% risk of death or MI at 3
years. This high rate is likely secondary to both
false-negative studies for significant CAD by
SPECT MPI and to the increased prevalence of
mild stenosis with a higher risk of plaque rupture. It
indicates that noninvasive techniques should be
improved to more accurately diagnose CAD, as
Figure 5. Cardiac Event Rates in Diabetics and Nondiabetics
With Normal Stress MPI
Kaplan-Meier curves of survival free of cardiac death in diabetic
and nondiabetic patients with normal stress myocardial perfusiont
imaging (MPI). Reprinted, with permission, from Giri et al. (23).with the increased use of PET MPI, and that more
aggressive medical therapy should be pursued (32).
Signiﬁcance of SPECTMPI in patients with chronic renal
disease. In recent years, it has become quite appar-
ent that patients with chronic kidney disease
(CKD) are at high risk of future cardiac events. The
risk of all-cause mortality, cardiac mortality, and
prevalence of cardiovascular disease increases signif-
icantly in proportion to the decrease in renal func-
tion as measured by the estimated glomerular fil-
tration rate (eGFR) (33,34). CKD patients have
more than a 10- to 20-fold increased risk of cardiac
death compared with age- and sex-matched sub-
jects without CKD (35). Diabetic patients with
CKD have a higher cardiac event rate than nondi-
abetic patients with CKD. Many patients with
advanced CKD including those on dialysis may not
manifest chest pain with severe CAD. Nephrolo-
gists who are considering patients for renal trans-
plantation most often refer patients to either coro-
nary angiography or noninvasive stress imaging for
risk stratification and detection of CAD. Some
CKD patients with known CAD may also be
risk-stratified again when renal dysfunction be-
comes progressive.
Several studies have been published showing
evidence of the value of stress SPECT MPI for
prognostication in patients with CKD. In a pre-
dominantly male (97%) cohort with a high preva-
lence of diabetes (40%) and CAD (45%), Hakeem
et al. (36) found a substantial increase in cardiac
death once the eGFR decreased to 60 and the
SSS exceeded 8.0. The annual rate of all-cause
mortality and subsequent nonfatal MI was signifi-
cantly higher in patients with an eGFR of 60 and
perfusion defects compared with those with an
eGFR of 60 with similar perfusion abnormalities.
Patients with an eGFR of60 and normal findings
on SPECT studies had an annual cardiac death rate
of 0.8% versus 9.5% in those with defects demon-
strated on SPECT and an eGFR of 60. In a
ubsequent publication by Hakeem et al. (37) in a
ohort undergoing renal transplantation, the annual
ardiac death rate was 16.8% for patients with CKD
nd diabetes who had an SSS 8. The highly
elective nature of these studies may limit their
eneralizability. Al-Mallah et al. (38) also showed
hat the risk of all-cause mortality increased with
orsening kidney function. Furthermore, at each
tage of impaired renal function, patients with
bnormal findings on SPECT MPI had an in-
reased risk of adverse events. The magnitude of
otal perfusion defect and ischemia on MPI was
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1312associated with worse outcome after adjusting for
confounding variables including GFR and ejection
fraction. Venkataraman et al. (39) showed that the
larger the defect size was on vasodilator stress MPI,
the worse the prognosis was for patients on long-
term hemodialysis. Risk stratification was better
achieved using defect size as the prognostic variable
as opposed to the extent of angiographic CAD (Fig. 6).
Interestingly, the event rate for patients with no
significant stenosis was similar to the event rate for
patients with 1- and 2-vessel disease.
Thus, these studies suggest that stress MPI can
identify high-risk patients with CKD. Greater ex-
tents of inducible perfusion abnormalities and
greater degrees of renal dysfunction are associated
with higher risks of cardiac complications. What is
yet to be ascertained is whether coronary revascu-
larization improves outcomes in such patients with
CKD and abnormal findings on SPECT MPI. No
randomized studies have been performed compar-
ing medical therapy with revascularization plus
Figure 6. Survival in End-Stage Renal Disease Stratiﬁed by Exte
Kaplan-Meier survival curves for patients with end-stage renal disea
sion defect size (A) and extent of obstructive coronary artery diseas
kataraman et al. (39). Abbreviations as in Figure 3.medical therapy in patients with advanced CKD
and abnormal findings on MPI.
MPI risk assessment in women and the elderly.
SPECT MPI is an especially important risk assess-
ment tool in elderly patients. Many elderly patients
have comorbidities or physical deconditioning that
render them incapable of performing exercise stress.
MPI in the elderly has been shown to be safe and
effective, with a low rate of cardiac events after
normal perfusion studies similar to that for younger
patients (40). Hachamovitch et al. (41) showed an
incremental value of ischemia over other clinical
data in 5,200 patients 75 years of age and older.
This proven benefit of MPI is especially important
given the diminished role of coronary CTA in the
elderly due to a higher prevalence of coronary artery
calcification.
Women undergoing evaluation for ischemia are a
large subgroup that has long been thought by many
to require SPECT MPI imaging due to a higher
false-positive rate on stress ECG alone. Observa-
f CAD and SPECT Defect Size
tratiﬁed by single-photon emission computed tomography perfu-
n coronary angiography (B). Adapted, with permission, from Ven-nt o
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1313tional cohorts (42,43), such as the 2,225-patient
study by Cerci et al. (43), have shown an incremen-
tal prognostic benefit of SPECT MPI over other
clinical variables and left ventricular function. How-
ever, the WOMEN study of 824 women random-
ized to exercise ECG versus exercise MPI found
comparable major adverse cardiac event (MACE)
rates in women with normal test results (0.4% for
exercise ECG vs. 1.2% for exercise MPI) (44).
These findings suggest that similar low-risk pa-
tients with good functional capacity and no known
CAD should undergo exercise ECG as their initial
test for ischemia.
RISK ASSESSMENT BY CARDIAC PETMPI
Myocardial ischemia evaluation by PET MPI. PET
MPI has many advantages over SPECT, including
improved spatial and temporal resolution, intrinsic
attenuation correction, and increased count sensi-
tivity. These benefits lead to improved image qual-
ity, diagnostic accuracy, interpretive confidence,
and detection of balanced ischemia (32,45).
Despite these advantages, PET MPI has his-
torically been underused due to costly equipment,
the need for a local cyclotron for tracer genera-
tion, a paucity of prognostic information, and the
inability to use exercise as the mode of stress. The
use of PET MPI is now increasing due to
resolution of many of these limitations. Equip-
ment costs are decreasing, rubidium-82 (82Rb)
can be generated without a cyclotron, and a novel
[18]-fluorodeoxyglucose (18F)– based tracer is
under evaluation that will allow exercise stress
testing (45,46).
As PET MPI has become more common, the
prognostic literature has become more robust. PET
perfusion abnormalities have been shown to provide
incremental prognostic value by chi-square analysis
in 4 major studies totaling 3,897 subjects (47–50).
Marwick et al. (47) showed the presence and extent
of ischemic myocardium to predict a composite of
cardiac death, nonfatal MI, late revascularization,
and unstable angina in 685 patients undergoing
dipyridamole 82Rb PET MPI. Yoshinaga et al. (49)
tratified 367 patients undergoing 82Rb PET by
SSS and found a stepwise increase in the rates of
cardiac death and nonfatal MI at a mean follow-up
of 3.7 years as the SSS increased: 0.4% for an SSS
4; 2.3% for an SSS of 4 to 7; and 7.0% for an SSS
8. It should be noted that 29 of the 46 events
(63.0%) were revascularization procedures rather
than hard cardiac events. An important novel find-ing of this study was that patients who were referred
for PET MPI after 99mTc-SPECT had a markedly
ifferent cardiac event rate with a normal versus
bnormal PET SSS (1.3% and 15.2%, p  0.001,
espectively). However, it should be noted that 1
onfatal MI was the only one of 11 events that was
hard.”
A study by Dorbala et al. (50) included a much
arger sample size of 1,432 patients who underwent
asodilator 82Rb PET MPI with fewer exclusions
nd contemporary imaging techniques. Over a
ean follow-up of 1.7 years, the percentage of
schemic myocardium correlated closely with the
isk of cardiac death or nonfatal MI. Patients
ithout ischemia had a 0.7% annualized event rate,
hich increased to 11% for those with 20% LV
schemia (Fig. 7). The percentage of ischemic
yocardium provided incremental prognostic value
oth for these cardiac events (p  0.04) and for
ll-cause mortality (p  0.006). A similar study of
,441 patients by Lertsburapa et al. (48) showed the
SS by 82Rb PET MPI to predict all-cause mor-
ality (2.4% for an SSS of 0 to 3; 4.1% for an SSS
f 4 to 8; 6.9% for an SSS 8; p  0.001). This
tudy also showed the LVEF to provide incremen-
al prognostic information as with SPECT.
However, in contrast to LVEF determination by
PECT, the gated 82Rb PET images are acquired
t the time of stress rather than after a delay.
Figure 7. Cardiac Events Stratiﬁed by Percentage of Ischemic
Myocardium on Rb-82 PET MPI
Kaplan-Meier curves of survival free of cardiac events as a function
percentage of ischemic myocardium in patients undergoing rubidiu
positron emission tomography (PET) myocardial perfusion imaging
Higher ischemic burden signiﬁcantly increases the risk of cardiac evof the
m-82
(MPI).
ents(p  0.0001). Reprinted, with permission, from Dorbala et al. (50).
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1314Accordingly, changes in LV function between rest
and stress have increased diagnostic and prognostic
significance. In 510- and 1,432-patient studies,
Al-Mallah et al. (38) elegantly showed that the
LVEF reserve (stress LVEF  rest LVEF) is a
strong independent predictor of severe ischemia,
left main/3-vessel CAD, and adverse events. Pa-
tients with left main/3-vessel CAD have a mean
reserve of 6.7%. On the other hand, an LVEF
reserve of 5% has a negative predictive value of
97% for excluding severe left main/3-vessel CAD.
An LVEF reserve of 0 is associated with a
2-fold increase in cardiac events and all-cause
mortality (Fig. 8). LVEF reserve provided incre-
mental prognostic value over clinical variables and
PET perfusion results (50). Therefore, a positive
LVEF reserve in the setting of a normal perfusion
result is reassuring, whereas a negative LVEF re-
serve may warrant further testing, even in the
setting of normal perfusion. Further study of this
phenomenon with adenosine stress (which may lead
to less prolonged ischemia than dipyridamole due to
its shorter half-life) is warranted (45).
Although there is a wealth of multicenter studies
assessing prognosis with SPECT MPI, the current
PET MPI prognostic literature is based on single-
center retrospective analyses and could benefit from
prospective multicenter validation studies (45).
SPARC (Study of Myocardial Perfusion and Cor-
onary Anatomy Imaging Roles in CAD) is a 41-
center observational registry that will help better
characterize the prognostic role of PET MPI and
PET-CT (51).
Figure 8. Effect of LVEF Reserve on Cardiac Events and
Mortality
Rates of cardiac death/nonfatal myocardial infarction and all-
cause mortality by left ventricular ejection fraction (LVEF)
reserve in patients undergoing rubidium-82 positron emission
tomography myocardial perfusion imaging. Event rates increase
with LVEF reserve 0% (p  0.001). Reprinted, with permission,
from Dorbala et al. (50).ADVANCES IN SPECT AND PETMPI FOR
PROGNOSTIC EVALUATION
PET-CT fusion imaging. There are several future ad-
vances expected in PET MPI that will likely trans-
form the prognostic literature. Although there are
few robust prognostic data available for PET-CT,
this combined modality offers the potential to
simultaneously assess the presence of obstructive
CAD and evaluate its ischemic burden, thereby
overcoming the limitations inherent in each tech-
nique alone (52). Calcium scoring adds incremental
prognostic value to PET MPI. Nonetheless, 16% of
patients with ischemia have a calcium score of 0,
possibly due to obstructive soft plaque (53). For this
reason, coronary CTA is the anatomic test of choice
to assess the extent and severity of coronary athero-
sclerosis. However, coronary CTA is insufficient as
a single test for the assessment of atherosclerotic
disease because only 40% to 50% with 50%
stenoses on coronary CTA have evidence of myo-
cardial ischemia (54,55). Fusion of the PET and
CT images also allows for culprit lesion determina-
tion. Technical advances have made this a more
feasible option by significantly reducing the radia-
tion burden to consistently 10 mSv (52). Ad-
vances in molecular imaging may soon allow the
identification of vulnerable atherosclerotic plaques,
which may allow improved risk stratification and
selection of therapeutic goals (56).
An additional advantage of PET-CT angiogra-
phy over PET alone is the prognostic value of
nonobstructive CAD (57,58). In a meta-analysis of
9,592 patients, Hulten et al. (57) showed an incre-
mental increase in MACE for nonobstructive CAD
over no CAD (1.4% vs. 0.2%). The finding of
nonobstructive CAD may trigger more aggressive
risk factor modification, as shown in the EISNER
(Early Identification of Subclinical Atherosclerosis
by Noninvasive Imaging Research) study of the
effect of calcium scoring (59). A functional study
alone does not provide this information. The opti-
mal use of PET-CT has not been established. In
this era of cost-containment for cardiovascular im-
aging, assessment of the cost-effectiveness of this
technique and identification of the ideal clinical
indications and patient populations will be essential.
Improved diagnostic accuracy will not be enough.
For widespread adoption of PET-CT to occur, it
will need to reduce subsequent adverse cardiac
outcomes over testing with either PET or coronary
CTA alone. The SPARC observational registry
should assist in this evaluation (51).
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1315Absolute ﬂow quantiﬁcation and myocardial ﬂow re-
serve. Absolute myocardial blood flow in millime-
ters/grams/minutes can be quantified using PET
imaging. This technique allows the calculation of
the myocardial flow reserve (MFR), which is the
ratio of myocardial blood flow at peak hyperemia to
resting myocardial blood flow. MFR has been
shown to identify multivessel disease and predict
the extent of ischemia more accurately than relative
perfusion techniques (60,61). Equivocal studies
from flow heterogeneity at higher flow rates are
reduced as well (60). Prognostic data, although
limited, are starting to emerge. Herzog et al. (62)
assessed 229 patients who underwent 13N-
ammonia PET perfusion imaging. An abnormal
MFR 2.0 was found to be independently associ-
ated with the 3-year rate of both MACE (6.3% vs.
1.4%, p  0.05) and cardiac death (3.1% vs. 0.5%,
 0.05). MFR predicted an increased risk in
atients with abnormal perfusion (Fig. 9).
The most commonly used PET perfusion tracer
s 82Rb because of its availability without an on-site
yclotron. The decreased tracer uptake at higher
oronary flow rates necessitates a corrective factor,
ut absolute flow estimates correlate well with
3N-ammonia–derived values (63). Limited prog-
ostic data had been available for absolute flow
Figure 9. Cardiac Events Stratiﬁed by Perfusion Abnormalities a
Unadjusted Kaplan-Meier curves for survival free of major adverse c
reserve (CFR) (2.0) versus abnormal (2.0) in patients with abnorm
spective of perfusion ﬁndings. Reprinted, with permission, from Herzoguantification using this tracer. Fukushima et al.
64) retrospectively studied 224 patients undergoing
82Rb PET perfusion imaging and found that an
MFR less than the median for this population
(2.11) was associated with a hazard ratio of 2.93
for cardiac events. However, 2 recent papers have
strengthened the link of reduced MFR and adverse
cardiac outcomes. Ziadi et al. (65) demonstrated
that an MFR 2 was an independent predictor of
hard events (hazard ratio: 3.3) and MACE (hazard
ratio: 2.4). Murthy et al. (66) found a 5.6-fold
increase in the risk of cardiac death for those with
an MFR 1.5 and a correct reclassification of
34.8% of intermediate-risk patients.
Additional comparative effectiveness studies be-
tween absolute and relative flow techniques for the
assessment of clinical outcomes, cost-effectiveness,
and quality of life will be essential.
New PET tracers. Exercise capacity is one of the
most powerful prognostic markers obtained during
exercise stress testing (1,67). The inability to per-
form exercise stress testing has been a major limi-
tation of 82Rb and 13N-ammonia PET MPI. A
ovel 18F tracer in clinical evaluation has 90%
first-pass extraction and specific uptake across a
wide range of flow rates (46). It has a high signal-
to-noise ratio, and initial assessments of image
Coronary Flow Reserve
ac events and cardiac death stratiﬁed by normal coronary ﬂow
(A) and normal (B) perfusion. Abnormal CFR predicts events irre-nd
ardi
alet al. (62).
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1316quality with this agent are very promising, having
been judged superior to 13N-ammonia images in
arly animal studies (68). The long half-life (110
in) of 18F will allow exercise stress testing to be
erformed for PET MPI studies using this tracer.
ts long half-life will also allow centers without
n-site cyclotrons to engage in cardiac PET imag-
ng without the expense and subsequent high pa-
ient throughput required for 82Rb generator use
69). Absolute flow quantification will likely be
vailable with this tracer (70).
Improved statistical evaluation. Finally, more rigor-
ous statistical evaluation of the prognostic benefit
of SPECT and PET MPI should be undertaken.
Contemporary statistical techniques, such as the
net reclassification index (NRI), which assesses
the ability of a test to reclassify patients into their
proper risk categories, are now recommended
(71). This method is robust and easier to apply
clinically versus other existing techniques such as
area-under-the-curve analysis. For example,
Shaw et al. (72) used the NRI to determine that
the additional cost of correctly classifying 1
additional person at high or low risk of cardio-
vascular death or nonfatal MI was $615 for stress
MPI versus exercise stress ECG. Piccini et al.
(73) identified an increased risk of sudden cardiac
death in patients with CAD and an LVEF 35%
and increasing SSS. However, the NRI showed
that their SPECT-derived nomogram failed to
reclassify 77 of 79 sudden cardiac deaths as high
risk, providing an important clinical perspective.
Although it has not been widely used in the SPECT
prognostic literature, this statistical tool may assist in
comparing the effectiveness and appropriateness of
different imaging methods for prognostic assessment
in ischemic heart disease (74).
CONCLUSIONS
In summary, there is no doubt that variables derived
from stress MPI provide clinically useful prognostic
information in symptomatic patients with suspected
or known CAD. For many years, we have primarily
relied on exercise or pharmacological SPECT MPI
for detecting CAD and risk stratification. Quantita-
tive analysis of relative perfusion abnormalities (i.e.,
defect extent and magnitude relative to segment of
maximal tracer uptake) and functional information
derived from gated images have yielded more robustfor SPECT MPI has also been refined by introduc-
tion of appropriateness criteria and by greater consid-
eration to radiation risk versus clinical benefit (75).
The advent of stress-only imaging and emergence of
new camera hardware and software programs have
contributed to reducing radiation exposure from
SPECT MPI. We have a better understanding of why
some patients with multivessel CAD have uniform
tracer uptake on MPI, which may reflect balanced
ischemia and diffuse abnormal coronary flow reserve.
Quantitative dynamic PET imaging permits the de-
termination of absolute flow and coronary flow re-
serve, the ratio of peak stress flow to resting flow.
Using PET MPI with flow quantitation can thus
improve the detection of high-risk patients. Unfortu-
nately, this approach is not available in most nuclear
cardiology laboratories, but the advent of hybrid
PET-CT cameras should lead to more widespread
adoption of cardiac PET in major imaging centers.
With SPECT, patients with diffuse ischemia can
often be identified by nonperfusion variables such as
TID and regional dysfunction on gated images. Cer-
tain populations, such as symptomatic patients with
diabetes or CKD, benefit from noninvasive perfusion
assessment to identify high-risk subsets of patients
who have been shown to experience a high rate of
cardiac events. We may see more MPI studies being
performed in patients who have initially undergone
coronary CTA for chest pain and are found to have
intermediate lesions or extensive noninterpretable seg-
ments. MPI in these situations assess the physiologic
significance of such anatomic abnormalities.
Finally, in this era of cost-containment with respect
to the use of imaging tests, we need to decrease the use
of inappropriate tests. Possible strategies include elim-
inating the use of MPI in asymptomatic subjects as
the initial test for risk assessment or performing MPI
studies in asymptomatic patients after uncomplicated
revascularization. Undoubtedly, there will be further
advances in technology, and it is incumbent on inves-
tigators in the imaging field to determine their worth
versus less expensive technology. The application of
NRI concepts to new imaging tests or indications is
key to the understanding of the additional benefit of
an imaging modality to other known variables.
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